The FDA has issued a warning of rare but serious risk of heart attacks and death with these cardiac nuclear stress drugs used by patients who cannot tolerate the usual exercise test. FDA recommends avoiding these drugs in patients with unstable angina or cardiovascular instability since they are already at high risk. Healthcare professionals and patients are encouraged to submit a report for the the FDA’s MedWatch Program regarding any adverse reactions from these drugs. Have you reported a ADR to the MedWatch program recently?

For more information please click here